Drug Profile
Pelareorep - Oncolytics Biotech
Alternative Names: AN-1004; PO-BB0209; REOLYSIN; Reosyn; Reovirus; Reovirus - Oncolytics Biotech; Reovirus anticancer; Reovirus antitumour; Reovirus Serotype 3 - Dearing Strain; Respiratory Enteric Orphan virus; Wild-type reovirus - Oncolytics BiotechLatest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Oncolytics Biotech
- Developer Adlai Nortye; Canadian Cancer Society Research Institute; Mayo Clinic; National Cancer Institute (USA); Oncolytics Biotech; PrECOG; Roche; University of Leeds; University of Southern California
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Breast cancer; Head and neck cancer
- Phase II Brain cancer; Colorectal cancer; Fallopian tube cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Sarcoma
- Phase I/II Anal cancer; Glioma; Multiple myeloma
- Preclinical Acute myeloid leukaemia
- No development reported Glioblastoma; Liver cancer; Solid tumours
Most Recent Events
- 11 Apr 2024 Oncolytics Biotech plans to discuss with the FDA to align on the design and objectives of the registrational trial for Pelareorep for Metastatic breast cancer in Q2 2024
- 11 Apr 2024 Revive Therapeutics submits Type C meeting request to US FDA for registration-enabling trial for Pelareorep in HR+/HER2- metastatic breast cancer (mBC)
- 11 Apr 2024 Oncolytics Biotech plans a phase III registrational trial for HR+/HER2- metastatic breast cancer